
AstraZeneca Is Next to Reach MFN Deal with White House
Key Takeaways
- AstraZeneca will offer drugs at reduced prices in the US through the TrumpRx.gov platform, launching in 2026.
- The agreement aims to make prescriptions more affordable for low-income patients, including Medicaid recipients.
US President Donald Trump made the announcement that AstraZeneca is the second of 17 major pharmaceutical companies, after Pfizer, to agree to most-favored-nation pricing protocols.
What details have been reported about the AstraZeneca agreement?
AstraZeneca’s reported deal to lower drug prices in the US stands to make prescriptions more affordable for patients with lower incomes, including those on Medicaid (1). The TrumpRx platform will allow any companies that reach an MFN deal with the White House to sell their drugs directly to consumers at deep discounts, but the website is not expected to be made live until 2026.
Aside from AstraZeneca and Pfizer, the other 15 companies to receive letters outlining those plans were 
What other commitments does AstraZeneca have in the US?
The deal with the White House was the second major piece of news involving AstraZeneca in as many days. On Oct. 9, 2025, the company said it would be 
References
1. The White House. 
2. Lavery, P. 
3. Lavery, P. 
4. Lavery, P. 
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.




